Loading...
Publication
Imunoterapia no Cancro do Pulmão de Não Pequenas Células – Tolerância e Efeitos secundários
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 5.66 MB | Adobe PDF |
Authors
Abstract(s)
Introdução:
O cancro do pulmão de não pequenas células (CPNPC) representa a maioria dos casos de
cancro do pulmão e é uma das principais causas de mortalidade por doença oncológica a
nível mundial. A introdução da imunoterapia revolucionou o tratamento destes doentes,
apesar dos efeitos adversos que importa conhecer melhor na prática clínica.
Objectivos:
Avaliar a tolerância e os efeitos secundários associados à imunoterapia, em monoterapia ou
em associação com a quimioterapia, em doentes com CPNPC em contexto real.
Materiais e Métodos:
Estudo observacional retrospectivo, que incluiu 124 doentes com CPNPC tratados com
imunoterapia nos serviços de Pneumologia dos hospitais da Guarda e da Covilhã, entre
Julho de 2022 e Outubro de 2024. Foram analisados os efeitos adversos e a sua relação com
idade, sexo, hábitos tabágicos, comorbilidades, linha de tratamento e fármaco utilizado.
Resultados:
Verificou-se que, apesar da generalidade dos doentes tolerar bem a terapêutica, uma
percentagem relevante apresentou pelo menos um efeito secundário. As toxicidades mais
frequentemente observadas foram as cutâneas, endócrinas e respiratórias. A maioria dos
efeitos foi de grau ligeiro a moderado. Não se observaram associações estatisticamente
significativas entre a ocorrência de efeitos adversos e algumas das variáveis analisadas como
a idade, o género, os hábitos tabágicos ou a linha de tratamento. Não se verificou qualquer
associação estatisticamente significativa entre a presença de comorbilidades e a ocorrência
de efeitos secundários. Ainda assim, algumas podem potenciar o aparecimento dos efeitos
secundários pelo que requerem vigilância terapêutica adequada.
Conclusões:
A imunoterapia mostra-se eficaz e globalmente bem tolerada nos doentes com CPNPC. A
maximização dos seus benefícios terapêuticos requer uma monitorização atenta e uma
gestão precoce dos efeitos secundários. Este estudo reforça ainda a importância de uma
abordagem personalizada e multidisciplinar no acompanhamento dos doentes.
Introduction: Non-small cell lung cancer (NSCLC) accounts for most of the lung cancer cases, and remains one of the leading causes of cancer-related mortality worldwide. The introduction of immunotherapy has revolutionized the treatment of these patients, despite the adverse effects that require closer understanding in clinical practice. Objectives: To evaluate the tolerance and side effects associated with immunotherapy, either as monotherapy or in combination with chemotherapy, in patients with NSCLC in a real-world setting. Materials and Methods: This was a retrospective observational study that included 124 patients with NSCLC treated with immunotherapy in the Pulmonology Departments of the hospitals in Guarda and Covilhã between July 2022 and October 2024. Adverse effects and their relationship with age, sex, smoking status, comorbidities, line of treatment, and drug used were analyzed. Results: Although most patients tolerated the therapy well, a relevant proportion experienced at least one side effect. The most frequently observed toxicities were cutaneous, endocrine, and respiratory. Most adverse effects were mild to moderate in severity. No statistically significant associations were found between the occurrence of adverse effects and variables such as age, sex, smoking status, or line of treatment. Likewise, no statistically significant association was observed between comorbidities and the occurrence of side effects. Nevertheless, certain comorbidities may contribute to the development of adverse effects, thus requiring appropriate therapeutic monitoring. Conclusions: Immunotherapy appears to be effective and generally well tolerated in patients with NSCLC. Maximizing its therapeutic benefits requires careful monitoring and early management of side effects. This study also highlights the importance of a personalized and multidisciplinary approach in patient care.
Introduction: Non-small cell lung cancer (NSCLC) accounts for most of the lung cancer cases, and remains one of the leading causes of cancer-related mortality worldwide. The introduction of immunotherapy has revolutionized the treatment of these patients, despite the adverse effects that require closer understanding in clinical practice. Objectives: To evaluate the tolerance and side effects associated with immunotherapy, either as monotherapy or in combination with chemotherapy, in patients with NSCLC in a real-world setting. Materials and Methods: This was a retrospective observational study that included 124 patients with NSCLC treated with immunotherapy in the Pulmonology Departments of the hospitals in Guarda and Covilhã between July 2022 and October 2024. Adverse effects and their relationship with age, sex, smoking status, comorbidities, line of treatment, and drug used were analyzed. Results: Although most patients tolerated the therapy well, a relevant proportion experienced at least one side effect. The most frequently observed toxicities were cutaneous, endocrine, and respiratory. Most adverse effects were mild to moderate in severity. No statistically significant associations were found between the occurrence of adverse effects and variables such as age, sex, smoking status, or line of treatment. Likewise, no statistically significant association was observed between comorbidities and the occurrence of side effects. Nevertheless, certain comorbidities may contribute to the development of adverse effects, thus requiring appropriate therapeutic monitoring. Conclusions: Immunotherapy appears to be effective and generally well tolerated in patients with NSCLC. Maximizing its therapeutic benefits requires careful monitoring and early management of side effects. This study also highlights the importance of a personalized and multidisciplinary approach in patient care.
Description
Keywords
Efeitos Secundários Cancro do Pulmão de Não Pequenas Células Cemiplimab Icis Imunoterapia Nivolumab Pd-1 Pd-L1 Pembrolizumab Tolerância